Skip to main content

Table 1 Baseline characteristics before and after propensity-score matching

From: Catheter ablation or surgical therapy in moderate-severe tricuspid regurgitation caused by long-standing persistent atrial fibrillation. Propensity score analysis

  Pre-matching Post-matching
Catheter n = 279 Surgical n = 114 SMD Catheter n = 111 Surgical n = 111 SMD
Age, yrs 69.1 ± 4.2 68.3 ± 4.8 0.095 69.0 ± 4.7 68.8 ± 4.5 0.15
Male 153 (54.8) 60 (52.6) 0.209 60 (54.1) 58 (52.3) −0.177
BMI, kg/m2 22.8 ± 2.3 22.7 ± 2.7 0.097 22.7 ± 2.5 22.7 ± 2.5 0.074
NYHA Class 2.3 ± 0.4 2.5 ± 0.6 0.027 2.3 ± 0.5 2.3 ± 0.5 0.026
Smoking 71 (25.4) 30 (26.4) −0.158 28 (25.2) 29 (26.1) −0.127
Diabetes 29 (10.4) 13 (11.4) −0.202 12 (10.8) 12 (10.8) 0.049
Hypertension 61 (21.9) 27 (23.7) −0.148 25 (22.5) 26 (23.4) −0.196
Stroke 34 (12.2) 17 (14.9) 0.016 15 (13.5) 16 (14.4) 0
CAD 31 (11.1) 15 (13.2) 0.003 14 (12.6) 14 (12.6) 0.081
COPD 12 (4.3) 6 (5.3) 0.016 5 (4.5) 5 (4.5) −0.203
CHADS2 Score 0.68 ± 1.32 0.70 ± 1.82 0.058 0.69 ± 1.19 0.70 ± 1.23 0.076
Euro SCORE 0.75 ± 1.02 0.79 ± 1.10 −0.175 0.76 ± 1.09 0.78 ± 1.12 −0.274
AF duration, years 2.5 ± 1.1 3.3 ± 1.6 0.169 2.5 ± 1.2 2.6 ± 1.3 0
Medication
 ACE I 51 (18.2) 22 (19.3) 0.009 21 (18.9) 21 (18.9) 0.155
 ARB 27 (9.7) 13 (11.4) −0.011 11 (10.0) 12 (10.8) 0.176
 CCB 20 (7.1) 11 (9.6) −0.007 9 (8.1) 10 (9.0) −0.137
 Beta-blocker 52 (18.6) 14 (12.3) 0.136 15 (13.5) 14 (12.6) −0.127
 Digitalis 78 (28.0) 22 (19.3) 0.144 24 (21.6) 22 (19.8) −0.156
 Diuretics 83 (29.7) 24 (21.1) 0.113 26 (23.4) 24 (21.6) −0.121
 Amiodarone 100 (35.8) 30 (26.3) −0.421 32 (28.8) 30 (27.0) −0.17
LVESD, mm 36.1 ± 10.1 37.5 ± 11.6 0.013 36.9 ± 11.5 37.1 ± 10.8 0.105
LVEDD, mm 52.1 ± 5.8 53.7 ± 6.8 −0.163 52.8 ± 6.1 53.0 ± 6.3 0.161
sPAP, mmHg 39.1 ± 9.2 40.7 ± 6.2 −0.184 39.8 ± 8.9 40.0 ± 7.1 0.125
LAD, mm 52.1 ± 11.7 53.6 ± 10.8 −0.011 52.6 ± 10.3 52.9 ± 10.9 −0.055
LVEF, % 60.1 ± 8.2 58.6 ± 9.2 −0.127 59.6 ± 8.9 59.1 ± 9.0 0.071
RAA, mm2 19.7 ± 5.1 20.9 ± 3.5 −0.164 20.0 ± 4.9 20.1 ± 4.9 0.219
RVSI 2.0 ± 0.2 2.0 ± 0.5 −0.162 2.0 ± 0.3 2.0 ± 0.3 0.165
RVFAC, % 43.1 ± 4.8 42.2 ± 6.7 −0.243 42.7 ± 4.3 42.4 ± 5.1 −0.042
Tethering height, mm 7.1 ± 3.6 8.9 ± 3.9 −0.294 7.9 ± 3.4 8.2 ± 3.7 0.017
Tethering area, cm2 2.8 ± 0.8 3.7 ± 0.7 0.217 2.9 ± 0.9 3.2 ± 0.5 0
TR EROA, cm2 0.8 ± 0.4 0.9 ± 0.8 −0.127 0.8 ± 0.5 0.8 ± 0.7 −0.157
TR VC, cm 1.0 ± 0.4 1.0 ± 0.7 −0.133 1.0 ± 0.2 1.0 ± 0.3 0.075
TR grade 3.4 ± 0.7 3.7 ± 0.5 0.022 3.5 ± 0.5 3.6 ± 0.2 −0.095
TAD, cm 36.5 ± 4.1 39.1 ± 5.2 0.003 37.9 ± 4.9 38.8 ± 5.0 0.081
  1. ACEI Angiotensin-converting enzyme inhibitor, AF Atrial fibrillation, ARB Angiotensin receptor blocker; BMI Body mass index, CAD Coronary artery disease, CCB Calcium channel blocker, COPD Chronic obstructive pulmonary disease, EROA Effective regurgitant orifice area, LAD Left atrial diameter, LVEF Left ventricle ejection fraction, LVEDD Left ventricle end-diastolic dimension, LVESD Left ventricle end-systolic dimension, NYHA New York Heart Association, RAA Right atrial area, RVFAC Right ventricle fractional area change, RVSI Right ventricle sphericity index, SMD Standard mean diference, sPAP Pulmonary artery systolic pressure, TAD Tricuspid annulus diameter, TR Tricuspid regurgitation, VC Vena contracta